Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel. +91-44-28290956, Fax.+91-44-28290956
Email: investor.relations@apollohospitals.com, Website : www.apollohospitals.com

Extract of Statement of Unaudited Financial Results for the Three & Nine Months Ended December 31, 2021

(Rs. in Lakhs, except per share data)

Particulars	Standalone						Consolidated					
	Three months ended 31/12/2021	Preceding Three months ended 30/09/2021	Corresponding Three months ended 31/12/2020	Year to date figures for current period ended 31/12/2021	Year to date figures for previous period ended 31/12/2020	Previous year ended 31/03/2021	Three months ended 31/12/2021	Preceding Three months ended 30/09/2021	Corresponding Three months ended 31/12/2020	Year to date figures for current period ended 31/12/2021	Year to date figures for previous period ended 31/12/2020	Previous year ended 31/03/2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income from Operations (net)	2,85,799	2,83,149	2,36,794	8,69,293	6,75,038	9,17,119	3,65,608	3,72,269	2,76,535	11,16,362	7,71,660	10,60,500
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	27,672	28,903	15,530	80,533	891	18,582	36,747	38,299	18,534	1,05,559	(5,153)	16,082
Net Profit / (Loss) for the period (before Tax, after Exceptional and/or Extraordinary Items)	27,672	28,903	15,530	79,859	782	17,673	36,747	38,299	18,534	1,34,970	(1,609)	22,147
Net profit / (Loss) for the period after tax (after Exceptional and Extraordinary items)	17,541	18,589	10,622	51,136	(1,037)	10,516	24,325	26,742	13,415	1,01,135	(3,312)	13,677
Total Comprehensive Income for the period [comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	17,391	18,081	10,555	50,518	(1,693)	9,958	24,095	25,966	13,386	1,00,356	(3,848)	15,210
Paid up Equity Share Capital (Face value of Rs.5/- each)				7,189		7,189				7,189		7,189
Other Equity				5,59,778		5,12,973				5,45,357		4,52,293
Earnings Per Share of Rs. 5/- each												
Basic	*12.20	*12.93	*7.64	*35.56	*(0.74)	7.51	*15.88	*17.24	*9.38	*67.15	*(1.26)	10.74
Diluted	*12.20	*12.93	*7.64	*35.56	*(0.74)	7.51	*15.88	*17.24	*9.38	*67.15	*(1.26)	10.74
Networth				5,61,203		5,14,380						
Paid up Debt Capital				20,000		20,000						
Debenture Redemption Reserve				5,000		5000						
Capital Redemption Reserve				600		600						

Notes:

* Not Annualised

1. The above is an extract of the detailed format of financial results (both standalone and consolidated) for three and nine months ended December 31, 2021 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites www. nseindia.com and www.bseindia.com and also the company's website www.apollohospitals.com.
2. The unaudited financial results (Standalone and Consolidated) of Apollo Hospitals Enterprise Limited ("the Company") for the three and nine months ended December 31, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on February 10, 2022 and February 11, 2022, respectively and have been subjected to limited review by the statutory auditors.
3. For the items referred in the Regulation 52(4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchanges (BSE and NSE) and can be accessed on the URL (www.bseindia.com and www.nseindia.com)
4. The listed non-convertible debentures of the Company aggregating to Rs. 20,000 lakhs as on December 31, 2021 are secured by way of first charge on the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
5. The Company had received approval from the Regional Director, Ministry of Corporate Affairs on June 28, 2021 for the Scheme of Amalgamation with the following wholly owned subsidiary companies, with the Appointed Date being April 1, 2020:

   a. Apollo Home Healthcare (India) Limited and
   b. Western hospitals Corporation Private Limited

   Consequent to giving effect to the said Scheme of Amalgamation, the Company has created a provision against loan of Rs. 674 lakhs extended by Western Hospitals Corporation Private Limited, in earlier years, to Apollo Lavasa Health Corporation Limited, a subsidiary, due to its adverse business conditions. This provision has been disclosed under Exceptional Items in the standalone financial results.
6. The Board of Directors and the shareholders have approved in their meeting held on June 23, 2021, and August 14, 2021 respectively, a re-organisation through a slump sale of identified business undertaking comprising of the pharmacy distribution business including the online technology platform Apollo 24|7 and the Company's shareholding in Apollo Medicals Private Limited (AMPL) (an associate) to Apollo HealthCo Limited, a wholly owned subsidiary of the Company for a consideration of Rs.1,21,000 lakhs, subject to certain conditions precedent including receipt of requisite approvals from AMPL shareholders and secured creditors. Pending completion of the other conditions precedent to consummate the said transaction, the identified business undertaking is not available for immediate sale as prescribed under Ind AS 105, "Non-current Assets Held for Sale and Discontinued Operations" and consequently no effect for this transfer has been recorded in this standalone financial results.
7. CRISIL Ratings Limited has upgraded its rating on the Company's long term bank facilities and non-convertible debentures to CRISIL AA+/Stable from CRISIL AA/Stable and reaffirmed the short term rating at CRISIL A1+.
8. The front-end retail pharmacy business included in the standalone pharmacy segment ("divestment business") was transferred to Apollo Pharmacies Limited, pursuant to a Scheme of Arrangement, which was effective from September 1, 2020. The Company thereafter has identified Healthcare and Pharmacy Distribution as its operating and reportable segments. Healthcare segment represents hospitals and hospital based pharmacies. Pharmacy distribution segment represents the business of procurement and distribution of pharmaceutical, Fast Moving Consumer Goods (FMCG) and private label products.
   Consequently, the figures for the nine months ended December 31, 2021 are not comparable with the figures for the previous nine months ended December 31, 2020 respectively.
9. Pursuant to the approval accorded by the members through Postal Ballot to raise equity proceeds upto a sum of Rs 150,000 lakhs, the Company completed a Qualified Institutional Equity (QIP) placement in January 2021, allotting an additional 46,59,498 equity shares at a price of Rs 2,511 per share (face value Rs 5/- each) aggregating to a sum of Rs 116,999.99 lakhs. The utilisation of the QIP Issue proceeds upto December 31, 2021 is as follows:

Particulars	Amount in Rs. Lakhs
Fees paid to Lead Managers	1,071.37
Foreclosure of debts	20,928.62
Acquisition of equity stake in Apollo Multi Speciality Hospitals Limited	41,000.00
Balance amounts placed in Mutual Funds pending deployment as on 30th September 2021	54,000.00

10. The Company completed the acquisition of an additional 50% stake held by Gleneagles Development Pte Limited (erstwhile joint venturer) in Apollo Multi Specialty Hospitals Limited (AMSHL) (formerly known as Apollo Gleneagles Hospitals Limited), Kolkata on 22 April 2021 for a consideration of Rs. 41,000 lakhs. Consequently, AMSHL became a wholly owned subsidiary of the Company and has been consolidated effective from 22nd April 2021. The figures for the three and nine months ended December 31, 2021 are therefore not comparable with the figures for the, corresponding three and nine months ended December 31, 2020 respectively and the figures for the previous year ended March 31, 2021.The Company has completed the purchase price allocation based on the report certified by the independent valuer in respect of the identifiable assets acquired and liabilities assumed, resulting in a goodwill of Rs. 53,711 lakhs, which is presented within the Healthcare segment.
11. Assam Hospitals Limited (AHL), a subsidiary company, completed the acquisition of 64.42% of equity stake in Asclepius Hospitals and Healthcare Private Limited (AHHPL), Guwahati on November 12, 2021, for a consideration of Rs.10,000 lakhs. Consequently, AHHPL became the subsidiary of AHL with effect from the said date. Based on the information available at this time, the Company determined a preliminary purchase price allocation based on the provisional amounts of the identifiable assets acquired and liabilities assumed, resulting in a provisional goodwill of Rs.7,161 lakhs as on December 31, 2021, which is subject to finalisation of the purchase accounting. The goodwill arising out of the acquisition is presented within the Healthcare segment
12. Apollo Multi Speciality Hospitals Limited (AMSHL) (formerly known as Apollo Gleneagles Hospitals Limited), subsidiary company has completed acquisition of 100% stake in Apollo Hospitals North Limited (AHNL) on October 1, 2021 for a consideration of Rs.5 lakhs. Consequently, AHNL has become a wholly owned subsidiary of AMSHL.
13. The Honourable High Court of Karnataka on October 8, 2021 has set aside the order of the State of Karnataka, Revenue Department ("Revenue Department") initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company alleging non-compliance of certain conditions associated with the allotment of land to the said subsidiary company and have remitted it back to the Revenue Department for reconsideration and disposal. Based on legal opinion, the Company has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in their favour.

Place : Chennai
Date : 11th February, 2022

for APOLLO HOSPITALS ENTERPRISE LIMITED
DR. PRATHAP C REDDY
Executive Chairman